Loading...
Market
Will Optune Lua become the leading treatment for mNSCLC post-platinum chemotherapy by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Healthcare industry reports and treatment adoption studies
Story
FDA Approves Novocure’s Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy
Oct 15, 2024, 06:35 PM
The US FDA has approved Novocure's Optune Lua for the treatment of metastatic non-small cell lung cancer (mNSCLC). The approval allows Optune Lua to be used concurrently with PD-1/PD-L1 inhibitors or docetaxel for adult patients who have progressed on or after a platinum-based chemotherapy regimen. This decision is based on the results of the LUNAR study, which showed a statistically significant improvement in overall survival. The study was presented at ASCO in 2023. The approval is expected to positively impact Novocure's market cap. $NVCR shares are anticipated to see an uptick following the FDA approval.
View original story
Similar markets
Europe • 25%
Asia • 25%
South America • 25%
Africa • 25%
Yes • 50%
No • 50%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Yes • 50%
No • 50%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%